Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
41.49
-0.47 (-1.12%)
At close: Oct 23, 2026, 4:00 PM EDT
41.94
+0.45 (1.08%)
After-hours: Oct 23, 2026, 5:23 PM EDT
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
289
Market Cap
5.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 33.19M | 14.38M | 76.41% |
| Dec 31, 2021 | 18.82M | 3.41M | 22.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| CRISPR Therapeutics AG | 13.39M |
| CG Oncology | 6.23M |
| Dianthus Therapeutics | 1.90M |
SRRK News
- 3 days ago - Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 - Business Wire
- 7 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Scholar Rock resubmits MAA for apitegromab to the EMA - TheFly
- 15 days ago - Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - Business Wire
- 4 weeks ago - Scholar Rock added to Best Ideas List at Wedbush - TheFly
- 4 weeks ago - Scholar Rock price target raised to $77 from $76 at Truist - TheFly
- 4 weeks ago - Scholar Rock price target raised to $70 from $63 at JPMorgan - TheFly
- 5 weeks ago - Scholar Rock says FDA requested pregnancy safety study for Isembyld - TheFly